arGEN-X Recipient of Signature Award

5/14/2012 5:30:00 PM

/uploadedImages/CHA_Corporate/About/drn14765.jpg Dawn Van Dam, General Manager   

Congratulations to arGEN-X on wining our inaugural Signature Award™. The Signature Award™ honors organizations with promising biotechnologies, judged on the following criteria: 1) value proposition to the marketplace and 2) market or partner readiness. arGEN-X competed with 38 emerging companies for this prestigious award. 

Read more about the innovative antibody discovery technologies from arGEN-X. 



   

CHA Signature Award  

Press Releases
Cambridge Healthtech Associates™ Announces Results of Survey on Trends in Safety Biomarkers(2)
Cambridge Healthtech Associates™ and Nucro-Technics Announce New Market Investigation
Cambridge Healthtech Associates™ Names Dawn Van Dan General Manager

Translational Safety Biomarkers in Early Safety Assessment

Translational Safety Biomarkers in Early Safety Assessment      The Drug Safety Executive Council (DSEC) hosted a webinar last month entitled Translational Safety Biomarkers in Early Safety Assessment. The recording is available here. During the webinar we presented some findings from

Read More


  

 Our Communities 

 

Leaders dedicated to advancing the development of better and safer medicines.
Visit to learn more  

NGSLeaders 

Pioneers in advancing the use and value of next-generation sequencing technologies.Visit to learn more  
 

©2012 Cambridge Healthtech Associates™: 250 First Avenue, Suite 300, Needham, MA 02494